Alzheimers Disease Global Clinical Trials Review, H1, 2017

Alzheimers Disease Global Clinical Trials Review, H1, 2017


  • Products Id :- GDHC4113CTIDB
  • |
  • Pages: 833
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, "Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 20

Clinical Trials by Phase in E7 Countries 22

Clinical Trials in E7 Countries by Trial Status 23

Clinical Trials by Phase 24

In Progress Trials by Phase 25

Clinical Trials by Trial Status 26

Clinical Trials by End Point Status 27

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 31

Prominent Drugs 32

Latest Clinical Trials News on Alzheimer's Disease 33

Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch 33

Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference 33

Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease 33

Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II ASTROSTEM,' Stem Cell Drug for Alzheimers Disease Treatment in US 34

Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial 34

Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease 35

Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease 35

Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer 35

Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease 36

Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany 36

Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 36

Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's 37

Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 37

Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy 38

Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease 38

Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer's and Parkinson's Diseases 39

Feb 09, 2017: Xanamem research published in prestigious medical journal 39

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment 39

Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients 40

Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria 40

Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy 40

Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience 41

Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 42

Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial-XanADu 42

Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients 42

Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer's Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 43

Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial 43

Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans 43

Clinical Trial Profile Snapshots 45

Appendix 831

Abbreviations 831

Definitions 831

Research Methodology 832

Secondary Research 832

About GlobalData 833

Contact Us 833

Source 833

List of Figures

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017* 7

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 20

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

GlobalData Methodology 832

List of Tables

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017* 7

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017* 12

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 21

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017* 24

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pfizer Inc, Johnson & Johnson, Eisai Co Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Allergan Plc, AbbVie Inc

Alzheimer's Disease Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Alzheimer's Disease, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

select a license

Single User License
USD 2500 INR 162350
Site License
USD 5000 INR 324700
Corporate User License
USD 7500 INR 487050

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com